MCID: MXD010
MIFTS: 13

Mixed Epithelial Stromal Tumour malady

Categories: Cancer diseases

Aliases & Classifications for Mixed Epithelial Stromal Tumour

Aliases & Descriptions for Mixed Epithelial Stromal Tumour:

Name: Mixed Epithelial Stromal Tumour 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5088
NCIt 47 C37265
UMLS 69 C1334602

Summaries for Mixed Epithelial Stromal Tumour

MalaCards based summary : Mixed Epithelial Stromal Tumour is related to cystic nephroma. The drugs Carboplatin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include kidney.

Wikipedia : 71 A cystic nephroma, also known as multilocular cystic nephroma, mixed epithelial stromal tumour (MEST)... more...

Related Diseases for Mixed Epithelial Stromal Tumour

Diseases related to Mixed Epithelial Stromal Tumour via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 cystic nephroma 11.2

Symptoms & Phenotypes for Mixed Epithelial Stromal Tumour

Drugs & Therapeutics for Mixed Epithelial Stromal Tumour

Drugs for Mixed Epithelial Stromal Tumour (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 90)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
3
Dactinomycin Approved Phase 3 50-76-0 2019 457193
4
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
5
Etoposide Approved Phase 3 33419-42-0 36462
6
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
Doxil Approved June 1999 Phase 3 31703
9 Alkylating Agents Phase 3,Phase 1,Phase 2
10 Anti-Bacterial Agents Phase 3,Phase 2
11 Antibiotics, Antitubercular Phase 3,Phase 2
12 Anti-Infective Agents Phase 3,Phase 2
13 Antimitotic Agents Phase 3
14 Antineoplastic Agents, Alkylating Phase 3,Phase 1,Phase 2
15 Antineoplastic Agents, Phytogenic Phase 3
16 Antirheumatic Agents Phase 3,Phase 1,Phase 2
17 Etoposide phosphate Phase 3
18 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
19 Nucleic Acid Synthesis Inhibitors Phase 3
20 Topoisomerase Inhibitors Phase 3
21 Liver Extracts Phase 3,Phase 2,Phase 1
22 Adjuvants, Anesthesia Phase 3
23 Analgesics Phase 3
24 Analgesics, Opioid Phase 3
25 Anesthetics Phase 3
26 Anesthetics, General Phase 3
27 Anesthetics, Intravenous Phase 3
28 Central Nervous System Depressants Phase 3
29 Narcotics Phase 3
30 pancreatic polypeptide Phase 3
31 Peripheral Nervous System Agents Phase 3,Phase 2
32 Cola Nutraceutical Phase 3,Phase 2
33
Indinavir Approved Phase 2 150378-17-9 5362440
34
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
35
Amifostine Approved, Investigational Phase 1, Phase 2 20537-88-6 2141
36
Lenograstim Approved Phase 1, Phase 2 135968-09-1
37
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
38
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
39
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
40
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754 657311
41
nivolumab Approved Phase 2 946414-94-4
42
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
43
Metformin Approved Phase 2 657-24-9 14219 4091
44
Bevacizumab Approved, Investigational Phase 2 216974-75-3
45
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
46 Anti-HIV Agents Phase 2
47 Anti-Retroviral Agents Phase 2
48 Antiviral Agents Phase 2
49 Cytochrome P-450 CYP3A Inhibitors Phase 2
50 Cytochrome P-450 Enzyme Inhibitors Phase 2

Interventional clinical trials:

(show all 22)
id Name Status NCT ID Phase
1 Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor Unknown status NCT00047138 Phase 3
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
3 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
4 Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect Completed NCT00003425 Phase 1, Phase 2
5 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2
6 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2
7 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
8 Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 Completed NCT02150213 Phase 2
9 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
10 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2
11 Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary Active, not recruiting NCT00748657 Phase 2
12 Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Active, not recruiting NCT00416455 Phase 1, Phase 2
13 Breast Cancer - Anti-Progestin Prevention Study 1 Not yet recruiting NCT02408770 Phase 2
14 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
15 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1
16 A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen Completed NCT00623831 Phase 1
17 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00082823 Phase 1
18 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00083213 Phase 1
19 Collecting Tumor Samples From Patients With Gynecological Tumors Completed NCT00897442
20 Gene Mutation in Samples From Young Patients With Pleuropulmonary Blastoma Syndrome at Risk for Developing Cancer Completed NCT01353300
21 DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study Recruiting NCT01247597
22 Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome Recruiting NCT00565903

Search NIH Clinical Center for Mixed Epithelial Stromal Tumour

Genetic Tests for Mixed Epithelial Stromal Tumour

Anatomical Context for Mixed Epithelial Stromal Tumour

MalaCards organs/tissues related to Mixed Epithelial Stromal Tumour:

39
Kidney

Publications for Mixed Epithelial Stromal Tumour

Articles related to Mixed Epithelial Stromal Tumour:

id Title Authors Year
1
Exophytic benign mixed epithelial stromal tumour of the kidney: case report of a rare tumour entity. ( 20193076 )
2010
2
Aggressive mixed epithelial-stromal tumour of the kidney treated with chemotherapy and radiotherapy. ( 15581546 )
2004

Variations for Mixed Epithelial Stromal Tumour

Expression for Mixed Epithelial Stromal Tumour

Search GEO for disease gene expression data for Mixed Epithelial Stromal Tumour.

Pathways for Mixed Epithelial Stromal Tumour

GO Terms for Mixed Epithelial Stromal Tumour

Sources for Mixed Epithelial Stromal Tumour

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....